In the fight against cancer, personalized medicine has become a powerful tool—and the Jewish General Hospital is leading the way for this innovative approach to treatment through proteomics.
What is proteomics?
Simply put, protein analysis. But through this analysis, researchers can determine if a patient’s proteins have undergone gene mutation, which can help them find disease patterns and potentially more successful modes of individualized treatment.
“Genomics shows us a list of the ingredients of the body — while proteomics shows us what those ingredients produce. Understanding what’s going on in your body at the protein level may lead to a new understanding of how cancer happens.” – Danny Hillis*
“If genomics is a photograph, proteomics is a movie.” – Bruce Wright – Head, Division of Medical Sciences, University of Victoria.
Proteomics and the Jewish General Hospital
With the creation of not only a Clinical Proteomics Laboratory at the Segal Cancer Centre but also the first pan-Canadian proteomics program, the JGH is continually advancing the impact that proteomics and personalized medicine can have for cancer patients locally and around the world.
The development of new diagnostic tools and targeted therapies means potentially better outcomes for those with tumour metastasis, urological cancer and many other forms of disease.
*William Daniel “Danny” Hillis is an American inventor, engineer, mathematician, entrepreneur, and author. He is Judge Widney Professor of Engineering and Medicine at the University of Southern California
Dr. Johnson is the Director of the lymphoma tissue bank at the Jewish General Hospital—and she’s a Rider, too! Just like you, she’s working to give those with this disease an improved chance to fight it by furthering the research on how and why particular therapies impact lymphoma patients.
A large portion of her research focuses on particularly aggressive forms of lymphoma that target adolescents and young adults. While most lymphomas respond well to chemotherapy—some don’t. Dr. Johnson’s mission is to find out why this happens.
Patients that see Dr. Johnson are asked to participate in her research—samples taken from patients that aren’t required for diagnostic purposes are preserved for further study. She has found that the genetic footprint is different in each cell. A blood test can now tell her more about any genetic mutation and that genetically unstable cells are more prone to die. These samples are studied to see how some patients conquer the battle while others don’t.
“The basic definition of an incurable disease is that its cells won’t die.” She believes that in some forms of lymphoma, mutated genes and their proteins have become particularly resistant to chemotherapy and inhibit its effects. The lymphoma tissue bank is central to her work. Johnson explains. “That’s why I do research, I’m comforted by the fact that my work might help the next patient.”
Money from the ride will go specifically to fund the storage of blood from patients with lymphoma and/or other cancers treated with chemotherapy and immunotherapy. This valuable resource has been made available to multiple researchers across Quebec and Canada. It has already led to 7 successful grants and multiple publications.
What’s old is new again!
The Jewish General Hospital is continually at the cutting edge of cancer research and treatment, but in embracing a holistic approach to patient care, it also finds inspiration in practices thousands of years old.
Chinese medicine, which includes acupuncture, qigong and Chinese herbs, has become a vital part of the services offered at the Peter Brojde Lung Cancer Centre.
Each practice has been used for health and wellbeing for millenia, and as provided by Thi Tran, a physiotherapist and practitioner of traditional Chinese medicine, they offer patients an elevated level of care.
Did you know that the JGH Division of Urology is the first institution in Quebec to use image fusion to target prostate biopsy and the first in North America to treat prostate cancer patients with focal therapy using the HIFU Focal-one machine?
It is an essential tool in the active surveillance of prostate cancer and provides the improved diagnostic capabilities necessary to perform focal therapy using a High Intensity Focused Ultrasound (HIFU) Focal-one machine. This is an advanced type of targeted therapy that can effectively destroy specific areas of cancer within the prostate, while preserving normal prostate tissue and function; it is minimally invasive and has fewer side-effects than surgery or radiation.
The JGH acquired the Urostation Touch mobile platform, integrating 3D applications, along with an Ultrasound machine and reusable guides, for the Division of Urology. This technology, which is used to assist prostate biopsy procedures, combines MRI and ultrasound to create a 3D image of the prostate that can more accurately locate suspicious areas and help diagnose prostate cancer.
These technologies are essential to the ongoing development of the Division’s Prostate Cancer Targeting Centre into a centre of excellence for prostate cancer diagnosis and treatment.
The Jewish General Hospital has been fortunate over the years to partner with generous donors in providing quality medical care to the people of Montreal and Quebec.
As a Canadian pioneer in robotic minimally invasive surgery, the JGH is employing its da Vinci robot to its maximum capacity. An urgent challenge at this time is to acquire a 2nd advanced da Vinci robot.
The current da Vinci Robot has proven immensely successful and the demand for this minimally invasive technology is growing at a pace that outstrips its availability. It is currently used for patients in such areas as Urology (e.g., removal of the prostate and kidneys, removal of tumours from the kidneys, repairs to the ureter), Cardiac Surgery (e.g., repair or replacement of the heart’s mitral valve, repair of the tricuspid valve, closure of congenital holes, removal of benign tumours on the right side of the heart), Gynecologic Oncology (e.g. removal of the uterus, removal of tumours from the ovaries, repairs to the Fallopian tubes) and General Surgery (e.g., repair of a hiatus hernia in the esophagus, removal of the gall bladder, resection of the bowel, repair of the esophagus to improve swallowing). The volume of operations performed annually at the JGH using the da Vinci robot has risen steadily from the 100 that were planned at first to close to 300 this year. In all, the Jewish General performed close to 700 operations since 2007 using the da Vinci robot.
Dr. Walter Gotlieb, who has developed an international reputation in robotic gynaecological procedures, has published widely on his research and as been appointed Chief of McGill’s Faculty of Medicine Robotic Surgery Program.
Just two years after adding robot-assisted surgery to its high-tech medical repertoire, the Jewish General Hospital (JGH) has rapidly shot to the Canadian forefront of this sophisticated field, with the most surgeons performing the greatest number of operations in the widest range of medical specialties anywhere in the country.
According to Dr. Lawrence Rosenberg, JGH Surgeon-in-Chief, ten JGH surgeons have now been trained to use the da Vinci Surgical System for a broad array of procedures in such fields as urology, gynecology, general and cardiac surgery. Robot-assisted surgery has proved to be particularly effective in treating prostate and gynecological cancers, since its use results in significantly shorter hospital stays, substantially less blood loss and a decreased risk of complications. This has prompted the Jewish General Hospital to take full advantage of the da Vinci Surgical System by performing nearly 450 operations during the past 19 months, with between four to six surgeries currently performed per week.
In robot-assisted surgery, the robotic arms—three bearing surgical instruments, and the fourth carrying a tiny threedimensional, high-definition video camera and light—are passed through small incisions and into the patient’s body. The surgeon, sitting at a special console, uses hand controls and foot pedals to manipulate all of the robotic arms with unprecedented precision and with greater flexibility than that of the human wrist.
Imagine if you walked through your front door only to discover you’d shrunk by about 1500 million times! If you stepped into your living room, you would not see chairs, tables, computers, and your family but atoms, molecules, proteins, and cells – shrunk down to the “nanoscale.” You’d not only see the atoms that everything is made from—you’d actually be able to move them around!
Now suppose you started moving them around and sticking the atoms together in new and interesting ways. Imagine the possibilities of all the new things you could create. Everything from brand new medicines to ultra-fast computer chips. Making new things on this incredibly small scale is called “nanotechnology” and it’s one of the most exciting and fast-moving areas of science and technology today.
How is nanorobotics used in cancer treatments?
The major problem in cancer therapeutics is ‘tumor resistance’, the ability of some cells in a tumor to overcome the attack of a variety of treatments. Working with the École Polytechnique (EP) at the Université de Montreal, the Chief of Radiation Therapy at the Segal Cancer Centre, Professor Té Vuong, has embarked on a paradigm-shifting project on nanorobotics in cancer therapy.
EP Professor Sylvain Martel has discovered bacteria which essentially eat iron, which makes them magnetic. They can then be loaded with any anti-cancer agent, and in the magnetic field of an MRI, they can be actively localized into tumours. More than that, it turns out that they automatically move into the area of tumours which are low in oxygen (hypoxic), usually resistant to all treatments, including radiotherapy. The search for ‘hypoxic cell sensitizers’ has been a hunt for the Holy Grail for decades, and we appear to have found an effective approach to this major therapeutic challenge.
The nanorobotic vision:
To offer next generation treatment for patients with cancer by establishing a new hybrid program of nanorobotic guided treatment to deliver drugs targeted to tumors in conjunction with state-of-the-art radiation treatment.
The association of the Jewish General Hospital (JGH) with Polytechnique was established to innovate solutions to treatment barriers. Polytechnique is world renowned for Research and development in high technology. The JGH is a leading research centre for novel cancer treatments. The JGH and Polytechnique have been collaborating closely and well over the last 4 years.
This project will integrate a graduate program in oncology, bringing novel technologies to the clinics to benefits not only to Canadians but mankind.